| 86.85 -2.05 (-2.31%) | 04-19 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 107.66 | 1-year : | 113.29 |
| Resists | First : | 92.17 | Second : | 97 |
| Pivot price | 90.11 |
|||
| Supports | First : | 84.37 | Second : | 70.2 |
| MAs | MA(5) : | 87.08 |
MA(20) : | 90.31 |
| MA(100) : | 85.21  |
MA(250) : | 67.04 |
|
| MACD | MACD : | -0.6 |
Signal : | 0 |
| %K %D | K(14,3) : | 29 |
D(3) : | 24.4 |
| RSI | RSI(14): 44.8 |
|||
| 52-week | High : | 101 | Low : | 43.88 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ BPMC ] has closed above bottom band by 21.6%. Bollinger Bands are 25.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 89.95 - 90.41 | 90.41 - 90.76 |
| Low: | 83.59 - 84.05 | 84.05 - 84.41 |
| Close: | 86.1 - 86.89 | 86.89 - 87.5 |
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Thu, 18 Apr 2024
Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024 - BioSpace
Thu, 11 Apr 2024
Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted ... - Yahoo Finance
Fri, 05 Apr 2024
Risks To Shareholder Returns Are Elevated At These Prices For Blueprint Medicines Corporation (NASDAQ:BPMC) - Simply Wall St
Thu, 04 Apr 2024
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Fri, 29 Mar 2024
Blueprint Medicines Corporation (NASDAQ:BPMC): When Will It Breakeven? - Yahoo Finance
Fri, 23 Feb 2024
Blueprint Medicines Highlights AYVAKIT® (avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell ... - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 61 (M) |
| Shares Float | 61 (M) |
| Held by Insiders | 0.8 (%) |
| Held by Institutions | 108 (%) |
| Shares Short | 4,370 (K) |
| Shares Short P.Month | 5,140 (K) |
| EPS | -8.37 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.14 |
| Profit Margin | -203.4 % |
| Operating Margin | -146.1 % |
| Return on Assets (ttm) | -25.4 % |
| Return on Equity (ttm) | -157.2 % |
| Qtrly Rev. Growth | 85.5 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 4.07 |
| EBITDA (p.s.) | -7.76 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -437 (M) |
| Levered Free Cash Flow | -239 (M) |
| PE Ratio | -10.38 |
| PEG Ratio | 0.1 |
| Price to Book value | 40.58 |
| Price to Sales | 21.32 |
| Price to Cash Flow | -12.18 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|